Concepedia

Silvina Gallo

SG

11

Publications

2K

Citations

11

H-Index

1994

Active since

Affiliations

Pfizer (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Pfizer (Germany)

Nantes Université

Pfizer (United Kingdom)

Silvina Gallo is an author at Pfizer (United States) specializing in medicine, cardiovascular pharmacology, and pharmacotherapy.

Top concepts

Publications per year

1994–2021

11

Publications

11

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

Christopher P. Cannon, Richard E. Pratley, Samuel Dagogo‐Jack et al. · New England Journal of Medicine · 2020 · 1.4K citations · Full text

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV)

Christopher P. Cannon, Darren K. McGuire, Richard E. Pratley et al. · American Heart Journal · 2018 · 202 citations · Full text

Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study

M Hanefeld, Carsta Koehler, Silvina Gallo et al. · Cardiovascular Diabetology · 2007 · 77 citations · Full text

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial

Silvina Gallo, B Charbonnel, Allison Goldman et al. · Diabetes Obesity and Metabolism · 2019 · 63 citations · Full text

DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV)

Christopher P. Cannon, Darren K. McGuire, Richard E. Pratley et al. · Journal of the American College of Cardiology · 2018 · 59 citations

, , +6

Rows per page

1–5 of 11